Patents by Inventor George J. Broze

George J. Broze has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for using lipoprotein associated coagulation inhibitor to treat sepsis
    Patent number: 7662774
    Abstract: A method for prophylactically or therapeutically treating sepsis or septic shock is described, wherein an inhibitor to tissue factor is administered to septic patients. Additionally, a method for treating inflammation is described wherein the inhibitor is administered to patients. This inhibitor is termed lipoprotein associated coagulation inhibitor, or commonly LACI. It is 38 kD and has 276 amino acids. LACI has now been shown to be useful for the treatment of sepsis, septic shock and inflammation.
    Type: Grant
    Filed: July 15, 2004
    Date of Patent: February 16, 2010
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Abla A. Creasey, George J. Broze
  • Methods for isolating tissue factor inhibitor
    Patent number: 7060805
    Abstract: A cDNA clone having a base sequence for human tissue factor inhibitor (TFI) has been developed and characterized and the amino acid sequence of the TFI has been determined.
    Type: Grant
    Filed: July 9, 2004
    Date of Patent: June 13, 2006
    Assignees: Pfizer Inc., Washington University
    Inventors: Tze Chein Wun, Kuniko K. Kretzmer, George J. Broze, Jr.
  • Protein Z-dependent protease inhibitor
    Patent number: 6841534
    Abstract: The disclosure describes the purification and isolation of a novel human protein Z-dependent protease inhibitor (ZPI) from plasma characterized as having a molecular weight of about 72 kDa, being a single chain protein with an N-terminal amino acid sequence of LAPSPQSPETPA, and which produces a rapid inhibition of factor Xa in the presence of human protein Z (PZ), calcium ions and cephalin. The disclosure further describes the isolation and cloning of the ZPI cDNA from a human cDNA library. The ZPI cDNA is 2.44 kb in length and has an open reading frame that encodes the 423 residue mature ZPI protein and a 21 residue signal peptide. PZ, ZPI and the combination of PZ and ZPI are used to inhibit blood coagulation.
    Type: Grant
    Filed: January 10, 2002
    Date of Patent: January 11, 2005
    Assignee: Washington University
    Inventor: George J. Broze, Jr.
  • DNA clone of human tissue factor inhibitor
    Publication number: 20040265981
    Abstract: A cDNA clone having a base sequence for human tissue factor inhibitor (TFI) has been developed and characterized and the amino acid sequence of the TFI has been determined.
    Type: Application
    Filed: July 9, 2004
    Publication date: December 30, 2004
    Applicant: G. D. SEARLE & CO.
    Inventors: Tze Chein Wun, Kuniko K. Kretzmer, George J. Broze
  • Nucleic acids encoding human tissue factor inhibitor
    Patent number: 6806360
    Abstract: A cDNA clone having a base sequence for human tissue factor inhibitor (TFI) has been developed and characterized and the amino acid sequence of the TFI has been determined.
    Type: Grant
    Filed: March 4, 2003
    Date of Patent: October 19, 2004
    Assignee: G.D. Searle & Co.
    Inventors: Tze Chein Wun, Kuniko K. Kretzmer, George J. Broze, Jr.
  • Protein Z-dependent protease inhibitor
    Publication number: 20040186053
    Abstract: The disclosure describes the purification and isolation of a novel human protein Z-dependent protease inhibitor (ZPI) from plasma characterized as having a molecular weight of about 72 kDa, being a single chain protein with an N-terminal amino acid sequence of LAPSPQSPETPA, and which produces a rapid inhibition of factor Xa in the presence of human protein Z (PZ), calcium ions and cephalin. The disclosure further describes the isolation and cloning of the ZPI cDNA from a human cDNA library. The ZPI cDNA is 2.44 kb in length and has an open reading frame that encodes the 423 residue mature ZPI protein and a 21 residue signal peptide. PZ, ZPI and the combination of PZ and ZPI are used to inhibit blood coagulation.
    Type: Application
    Filed: December 18, 2003
    Publication date: September 23, 2004
    Inventor: George J. Broze
  • Method for using lipoprotein associated coagulation inhibitor to treat sepsis
    Publication number: 20030171292
    Abstract: A method for prophylactically or therapeutically treating sepsis or septic shock is described, wherein an inhibitor to tissue factor is administered to septic patients. Additionally, a method for treating inflammation is described wherein the inhibitor is administered to pateints. This inhibitor is termed lipoprotein associated coagulation inhibitor, or commonly LACI. It is 38 kD and has 276 amino acids. LACI has now been shown to be useful for the treatment of sepsis, septic shock and inflammation.
    Type: Application
    Filed: February 19, 2003
    Publication date: September 11, 2003
    Inventors: Abla A. Creasey, George J. Broze
  • DNA clone of human tissue factor inhibitor
    Publication number: 20030166194
    Abstract: A cDNA clone having a base sequence for human tissue factor inhibitor (TFI) has been developed and characterized and the amino acid sequence of the TFI has been determined.
    Type: Application
    Filed: March 4, 2003
    Publication date: September 4, 2003
    Applicant: G. D. SEARLE & CO.
    Inventors: Tze Chein Wun, Kuniko K. Kretzmer, George J. Broze
  • Methods for detecting human tissue factor inhibitor
    Patent number: 6534276
    Abstract: Molecules, such as antibodies, with binding specificity for Tissue factor Inhibitor (TFI) or for polypeptides comprising one or more Kunitz domains of TFI can be used in methods to detect TFI or polypeptides containing a Kunitz domain of TFI in biological fluids. Either direct or indirect detection methods can be carried out.
    Type: Grant
    Filed: July 28, 2000
    Date of Patent: March 18, 2003
    Assignee: G. D. Searle & Company
    Inventors: Tze Chein Wun, Kuniko K. Kretzmer, George J. Broze, Jr.
  • Protein Z-dependent protease inhibitor
    Publication number: 20020183254
    Abstract: The disclosure describes the purification and isolation of a novel human protein Z-dependent protease inhibitor (ZPI) from plasma characterized as having a molecular weight of about 72 kDa, being a single chain protein with an N-terminal amino acid sequence of LAPSPQSPETPA, and which produces a rapid inhibition of factor Xa in the presence of human protein Z (PZ), calcium ions and cephalin. The disclosure further describes the isolation and cloning of the ZPI cDNA from a human cDNA library. The ZPI CDNA is 2.44 kb in length and has an open reading frame that encodes the 423 residue mature ZPI protein and a 21 residue signal peptide. PZ, ZPI and the combination of PZ and ZPI are used to inhibit blood coagulation.
    Type: Application
    Filed: January 10, 2002
    Publication date: December 5, 2002
    Inventor: George J. Broze
  • Protein Z-dependent protease inhibitor
    Patent number: 6369031
    Abstract: The disclosure describes the purification and isolation of a novel human protein Z-dependent protease inhibitor (ZPI) from plasma characterized as having a molecular weight of about 72 kDa, being a single chain protein with an N-terminal amino acid sequence of LAPSPQSPETPA, and which produces a rapid inhibition of factor Xa in the presence of human protein Z (PZ), calcium ions and cephalin. The disclosure further describes the isolation and cloning of the ZPI cDNA from a human cDNA library. The ZPI cDNA is 2.44 kb in length and has an open reading frame that encodes the 423 residue mature ZPI protein and a 21 residue signal peptide. PZ, ZPI and the combination of PZ and ZPI are used to inhibit blood coagulation.
    Type: Grant
    Filed: October 25, 2000
    Date of Patent: April 9, 2002
    Assignee: Washington University
    Inventor: George J. Broze, Jr.
  • Protein Z-dependent protease inhibitor
    Patent number: 6271367
    Abstract: The disclosure describes the purification and isolation of a novel human protein Z-dependent protease inhibitor (ZPI) from plasma characterized as having a molecular weight of about 72 kDa, being a single chain protein with an N-terminal amino acid sequence of LAPSPQSPETPA, and which produces a rapid inhibition of factor Xa in the presence of human protein Z (PZ), calcium ions and cephalin. The disclosure further describes the isolation and cloning of the ZPI cDNA from a human cDNA library. The ZPI cDNA is 2.44 kb in length and has an open reading frame that encodes the 423 residue mature ZPI protein and a 21 residue signal peptide. PZ, ZPI and the combination of PZ and ZPI are used to inhibit blood coagulation.
    Type: Grant
    Filed: October 25, 2000
    Date of Patent: August 7, 2001
    Assignee: Washington University
    Inventor: George J. Broze, Jr.
  • Protein Z-dependent protease inhibitor
    Patent number: 6265378
    Abstract: The disclosure describes the purification and isolation of a novel human protein Z-dependent protease inhibitor (ZPI) from plasma characterized as having a molecular weight of about 72 kDa, being a single chain protein with an N-terminal amino acid sequence of LAPSPQSPETPA, and which produces a rapid inhibition of factor Xa in the presence of human protein Z (PZ), calcium ions and cephalin. The disclosure further describes the isolation and cloning of the ZPI cDNA from a human cDNA library. The ZPI cDNA is 2.44 kb in length and has an open reading frame that encodes the 423 residue mature ZPI protein and a 21 residue signal peptide. PZ, ZPI and the combination of PZ and ZPI are used to inhibit blood coagulation.
    Type: Grant
    Filed: October 25, 2000
    Date of Patent: July 24, 2001
    Assignee: Washington, University
    Inventor: George J. Broze, Jr.
  • Protein Z-dependent protease inhibitor
    Patent number: 6245741
    Abstract: The disclosure describes the purification and isolation of a novel human protein Z-dependent protease inhibitor (ZPI) from plasma characterized as having a molecular weight of about 72 kDa, being a single chain protein with an N-terminal amino acid sequence of LAPSPQSPETPA, and which produces a rapid inhibition of factor Xa in the presence of human protein Z (PZ), calcium ions and cephalin. The disclosure further describes the isolation and cloning of the ZPI cDNA from a human cDNA library. The ZPI cDNA is 2.44 kb in length and has an open reading frame that encodes the 423 residue mature ZPI protein and a 21 residue signal peptide. PZ, ZPI and the combination of PZ and ZPI are used to inhibit blood coagulation.
    Type: Grant
    Filed: March 17, 1999
    Date of Patent: June 12, 2001
    Assignee: Washington University
    Inventor: George J. Broze, Jr.
  • Antibodies to tissue factor inhibitor
    Patent number: 6171587
    Abstract: A cDNA clone having a base sequence for human tissue factor inhibitor (TFI) has been developed and characterized and the amino acid sequence of the TFI has been determined. Antibodies having a binding region specific to human tissue factor inhibitor are disclosed.
    Type: Grant
    Filed: April 3, 1998
    Date of Patent: January 9, 2001
    Assignee: G. D. Searle and Company
    Inventors: Tze Chein Wun, Kuniko K. Kretzmer, George J. Broze, Jr.
  • Method for using lipoprotein associated coagulation inhibitor to treat sepsis
    Patent number: 6063764
    Abstract: A method for prophylactically or therapeutically treating sepsis or septic shock is described, wherein an inhibitor to tissue factor is administered to septic patients. Additionally, a method for treating inflammation is described wherein the inhibitor is administered to pateints. This inhibitor is termed lipoprotein associated coagulation inhibitor, or commonly LACI. It is 38 kD and has 276 amino acids. LACI has now been shown to be useful for the treatment of sepsis, septic shock and inflammation.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: May 16, 2000
    Assignee: Washington University & Chiron Corp.
    Inventors: Abla A. Creasey, George J. Broze
  • Human tissue factor inhibitor
    Patent number: 5849875
    Abstract: A cDNA clone having a base sequence for human tissue factor inhibitor (TFI) has been developed and characterized and the amino acid sequence of the TFI has been determined.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: December 15, 1998
    Assignee: G. D. Searle & Co.
    Inventors: Tze-Chein Wun, Kuniko K. Kretzmer, George J. Broze, Jr.
  • DNA clone of human tissue factor inhibitor
    Patent number: 5773251
    Abstract: A cDNA clone having a base sequence for human tissue factor inhibitor (TFI) has been developed and characterized and the amino acid sequence of the TFI has been determined.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: June 30, 1998
    Assignee: G.D. Searle & Co.
    Inventors: Tze-Chein Wun, Kuniko K. Kretzmer, George J. Broze, Jr.
  • Methods and compositions for inhibition of hepatic clearance of tissue factor pathway inhibitor
    Patent number: 5650391
    Abstract: The present invention discloses methods and compositions for inhibiting the hepatic clearance of Tissue Factor Pathway Inhibitor (TFPI) using receptor-associated protein.
    Type: Grant
    Filed: March 21, 1994
    Date of Patent: July 22, 1997
    Assignee: Jewish Hospital of St. Louis
    Inventors: Alan L. Schwartz, Ilka Warshawsky, George J. Broze
  • Human tissue factor inhibitor
    Patent number: 5466783
    Abstract: A cDNA clone having a base sequence for human tissue factor inhibitor (TFI) has been developed and characterized and the amino acid sequence of the TFI has been determined.
    Type: Grant
    Filed: July 15, 1993
    Date of Patent: November 14, 1995
    Assignees: Monsanto Company, Washington University
    Inventors: Tze-Chein Wun, Kuniko K. Kretzmer, George J. Broze, Jr.